These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 34169667)
61. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367 [TBL] [Abstract][Full Text] [Related]
62. Intergrating conventional MRI, texture analysis of dynamic contrast-enhanced MRI, and susceptibility weighted imaging for glioma grading. Su CQ; Lu SS; Han QY; Zhou MD; Hong XN Acta Radiol; 2019 Jun; 60(6):777-787. PubMed ID: 30244590 [TBL] [Abstract][Full Text] [Related]
63. Correlation of diffusion tensor, dynamic susceptibility contrast MRI and (99m)Tc-Tetrofosmin brain SPECT with tumour grade and Ki-67 immunohistochemistry in glioma. Alexiou GA; Zikou A; Tsiouris S; Goussia A; Kosta P; Papadopoulos A; Voulgaris S; Kyritsis AP; Fotopoulos AD; Argyropoulou MI Clin Neurol Neurosurg; 2014 Jan; 116():41-5. PubMed ID: 24309151 [TBL] [Abstract][Full Text] [Related]
64. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. Hakyemez B; Erdogan C; Ercan I; Ergin N; Uysal S; Atahan S Clin Radiol; 2005 Apr; 60(4):493-502. PubMed ID: 15767107 [TBL] [Abstract][Full Text] [Related]
65. Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. Ma B; Blakeley JO; Hong X; Zhang H; Jiang S; Blair L; Zhang Y; Heo HY; Zhang M; van Zijl PC; Zhou J J Magn Reson Imaging; 2016 Aug; 44(2):456-62. PubMed ID: 26788865 [TBL] [Abstract][Full Text] [Related]
66. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Chaskis C; Neyns B; Michotte A; De Ridder M; Everaert H Surg Neurol; 2009 Oct; 72(4):423-8. PubMed ID: 19150114 [TBL] [Abstract][Full Text] [Related]
67. Post-ictal changes presenting as late pseudoprogression on MRI and PET in a patient with diffuse glioma: Case report and brief literature review. Nair SM; Sahu A; Dasgupta A; Puranik A; Gupta T Neuroradiol J; 2024 Apr; 37(2):229-233. PubMed ID: 37002537 [TBL] [Abstract][Full Text] [Related]
68. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Patel P; Baradaran H; Delgado D; Askin G; Christos P; John Tsiouris A; Gupta A Neuro Oncol; 2017 Jan; 19(1):118-127. PubMed ID: 27502247 [TBL] [Abstract][Full Text] [Related]
69. Role of perfusion-weighted imaging at 3 Tesla in the assessment of malignancy of cerebral gliomas. Di Costanzo A; Pollice S; Trojsi F; Giannatempo GM; Popolizio T; Canalis L; Armillotta M; Maggialetti A; Carriero A; Tedeschi G; Scarabino T Radiol Med; 2008 Feb; 113(1):134-43. PubMed ID: 18338133 [TBL] [Abstract][Full Text] [Related]
70. Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis. Choi SH; Jung SC; Kim KW; Lee JY; Choi Y; Park SH; Kim HS J Neurooncol; 2016 Jun; 128(2):185-94. PubMed ID: 27108275 [TBL] [Abstract][Full Text] [Related]
71. Accuracy of Susceptibility-Weighted Imaging and Dynamic Susceptibility Contrast Magnetic Resonance Imaging for Differentiating High-Grade Glioma from Primary Central Nervous System Lymphomas: Meta-Analysis. Wu Y; Den Z; Lin Y World Neurosurg; 2018 Apr; 112():e617-e623. PubMed ID: 29371168 [TBL] [Abstract][Full Text] [Related]
72. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients. Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606 [TBL] [Abstract][Full Text] [Related]